Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Viardot

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Blood|June 19, 2014
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomasNiels Murawski, Gerhard Held, Marita Ziepert, et al.
Hematological Oncology|April 30, 2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paperSarah Bailly, Guillaume Cartron, Sridhar Chaganti, et al.
Haematologica|December 20, 2011
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphomaChuanhui Xu, Wouter Plattel, Anke van den Berg, et al.
The Lancet. Oncology|November 22, 2012
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)Norbert Schmitz, Maike Nickelsen, Marita Ziepert, et al.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Haematologica|June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma AllianceChristian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Hemasphere|September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM TrialMathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Leukemia & Lymphoma|February 8, 2025
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemiaFabian Lang, Andreas Voss, Guido Kobbe, et al.
Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Blood|June 19, 2014
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomasNiels Murawski, Gerhard Held, Marita Ziepert, et al.
Hematological Oncology|April 30, 2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paperSarah Bailly, Guillaume Cartron, Sridhar Chaganti, et al.
Haematologica|December 20, 2011
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphomaChuanhui Xu, Wouter Plattel, Anke van den Berg, et al.
The Lancet. Oncology|November 22, 2012
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)Norbert Schmitz, Maike Nickelsen, Marita Ziepert, et al.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Haematologica|June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma AllianceChristian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Hemasphere|September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM TrialMathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Leukemia & Lymphoma|February 8, 2025
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemiaFabian Lang, Andreas Voss, Guido Kobbe, et al.
Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Pageof 9